TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29957095

Group type: EXPERIMENTAL
Intervention: Primary goal of comfort
Number of subjects: 302

Group type: COMPARATOR
Intervention: Other goals
Number of subjects: 302
Study: 28594946

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring with biomass
Number of subjects: 120
Study: 26214111

Group type: EXPERIMENTAL
Intervention: Focused education and medication management intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual ED care
Number of subjects: 101
Study: 24026258

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study: 20850731

Group type: EXPERIMENTAL
Intervention: 0.30‐mg esterified estrogens and 0.30‐mg methyltestosterone combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esterified estrogens and methyltestosterone alone or in combination
Number of subjects: 0
Study: 19140846

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) in diabetic patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) in non-diabetic patients
Number of subjects: 17
Study: 16638478

Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison group (no hand massage)
Number of subjects: 60
Study: 14669930

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate + alpha-lipoic acid + sucrose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Creatine monohydrate + sucrose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Creatine monohydrate alone
Number of subjects: 16
Study: 10768801

Group type: EXPERIMENTAL
Intervention: Gimme 5 intervention (school-based media campaign, classroom workshops, school meal modification, parental involvement)
Number of subjects: 2213

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2213
Study: 8644543

Group type: EXPERIMENTAL
Intervention: Encircling buckling procedure (Group 2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Encircling with vitrectomy (Group 3)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Encircling with local buckling (Group 4)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Local buckling (Group 1)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All encircling procedures (Groups 2, 3, and 4)
Number of subjects: 88
Study: 1635737

Group type: EXPERIMENTAL
Intervention: Cytobrush/spatula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotton swab/spatula
Number of subjects: 0
Study: 31757266

Group type: EXPERIMENTAL
Intervention: One-day training in trauma inquiry plus a 1.5-hour refresher session 3 months later.
Number of subjects: 5204

Group type: COMPARATOR
Intervention: No training (control group).
Number of subjects: 5204
Study: 29775988

Group type: EXPERIMENTAL
Intervention: RT twice a week (G2X)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: RT three times a week (G3X)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-exercise control group (CG)
Number of subjects: 57
Study: 26738606

Group type: EXPERIMENTAL
Intervention: Neoadjuvant TAC chemotherapy with zoledronic acid
Number of subjects: 216

Group type: COMPARATOR
Intervention: Neoadjuvant TAC chemotherapy without zoledronic acid
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Variant T allele of 3129G > T in IGF1R (rs2016347)
Number of subjects: 216
Study: 25028067

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash administered for 1 min before dental manipulation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sterile water mouthrinse (control group)
Number of subjects: 101
Study: 23057665

Group type: COMPARATOR
Intervention: Iron‐folate (FeFol = standard care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein‐energy (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PE + MMN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid‐based nutritional supplement with or without additional MMN
Number of subjects: 0
Study: 20591543

Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine
Number of subjects: 0
Study: 17954806

Group type: EXPERIMENTAL
Intervention: Osteoporosis case manager intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 220
Study: 16282228

Group type: EXPERIMENTAL
Intervention: Brief counseling session using empowerment techniques, motivational interviewing, identification of stressors and individual coping strategies, and educational materials
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no counseling intervention)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Self-reporting of tobacco use
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cotinine analysis
Number of subjects: 62
Study: 12147200

Group type: EXPERIMENTAL
Intervention: Huangqi Jianzhong Tang
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10778587

Group type: EXPERIMENTAL
Intervention: Hartone 2 caps twice daily for 6 weeks and 1 cap twice daily for the next 6 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isosorbide mononitrate (ISMN) 20 mg twice daily
Number of subjects: 10
Study: 7874911

Group type: EXPERIMENTAL
Intervention: Hypercarbia stage (increased PaCO2 to > 55 torr)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate administration (4-mEq/kg iv dose)
Number of subjects: 15
Study: 2191636

Group type: EXPERIMENTAL
Intervention: Multiple-dose charcoal therapy (25 g of activated charcoal ingested at 4, 6, 8, and 10 hours after drug ingestion)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no charcoal therapy)
Number of subjects: 10
Study: 396084

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 9
Study: 31138321

Group type: EXPERIMENTAL
Intervention: Single purse-string anastomosis
Number of subjects: 500

Group type: COMPARATOR
Intervention: Double purse-string anastomosis
Number of subjects: 500
Study: 28689688

Group type: EXPERIMENTAL
Intervention: Lurasidone (20-80mg/d) combined with lithium or valproate
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo combined with lithium or valproate
Number of subjects: 496
Study: 25061715

Group type: EXPERIMENTAL
Intervention: Hybrid message containing both statistical and narrative descriptions of HPV
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: First-person narrative message
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both evidence type and narrative type
Number of subjects: 174
Study: 23380292

Group type: EXPERIMENTAL
Intervention: Antivenom
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21206933

Group type: EXPERIMENTAL
Intervention: +MAG
Number of subjects: 116

Group type: COMPARATOR
Intervention: -MAG
Number of subjects: 116
Study: 19404957

Group type: EXPERIMENTAL
Intervention: 10 mg VX-702 daily plus methotrexate (MTX)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: 10 mg VX-702 twice weekly plus methotrexate (MTX)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: 5 mg VX-702
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: 10 mg VX-702
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: VX-702 groups
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: VX-702
Number of subjects: 430
Study: 17468788

Group type: EXPERIMENTAL
Intervention: Electroacupuncture in conjunction with conventional rehabilitation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional rehabilitation alone
Number of subjects: 63
Study: 15542517

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11677802

Group type: EXPERIMENTAL
Intervention: Information to patient and family doctor
Number of subjects: 100

Group type: COMPARATOR
Intervention: No specific information about return to work (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Private insurance subgroup
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Panel patients subgroup
Number of subjects: 100
Study: 9039611

Group type: EXPERIMENTAL
Intervention: Dynamic gadolinium-enhanced MR angiography (MRA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Catheter angiography
Number of subjects: 65

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 65
Study: 8176573

Group type: EXPERIMENTAL
Intervention: High-dose therapy with corticotropin (ACTH) - 150 U/m2 per day for 3 weeks, 80 U/m2 per day for 2 weeks, 80 U/m2 every other day for 3 weeks, and 50 U/m2 per day every other day for 1 week, tapered to zero over 3 weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-dose therapy with corticotropin (ACTH) - 20 to 30 U/day for 2 to 6 weeks, tapered to zero over 1 week.
Number of subjects: 50
Study: 2855105

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg orally) + LVP (0.06 IU/kg i.v. over 1 h)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Loperamide (16 mg orally) + Placebo + LVP (0.06 IU/kg i.v. over 1 h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg orally) + CRH (1 micrograms/kg i.v. as bolus)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo + CRH (1 micrograms/kg i.v. as bolus)
Number of subjects: 11
Study: 31967742

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 44
Study: 30597583

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 36
Study: 29282027

Group type: EXPERIMENTAL
Intervention: DePuy Synthes® VA‐LCP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Medartis® Aptus Elbow
Number of subjects: 20
Study: 25158295

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High electrolyte drink
Number of subjects: 55

Group type: COMPARATOR
Intervention: Water
Number of subjects: 55
Study: 23839175

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%-benzoyl peroxide 2.5% gel (adapalene-BPO)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 285
Study: 21030529

Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling
Number of subjects: 1562

Group type: COMPARATOR
Intervention: Mailed self-help
Number of subjects: 1562
Study: 19121495

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing resin (Ortho-Coat) with Transbond Plus self-etching primer
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transbond Plus self-etching primer without fluoride resin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Antimicrobial self-etching primer (Clearfil Protect Bond) without fluoride resin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Antimicrobial self-etching primer (Clearfil Protect Bond) with fluoride resin (Ortho-Coat)
Number of subjects: 80
Study: 18063500

Group type: EXPERIMENTAL
Intervention: glyburide/metformin 2.5 mg/500 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: glyburide/metformin 5.0 mg/500 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: glyburide 5 mg b.i.d.
Number of subjects: 100

Group type: COMPARATOR
Intervention: metformin 500 mg b.i.d.
Number of subjects: 100
Study: 15094151

Group type: EXPERIMENTAL
Intervention: Supported treadmill ambulation training
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Controlled withdrawal of anti-spasticity medications
Number of subjects: 2
Study: 11601748

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg via Aerolizer
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg via Diskhaler
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9529028

Group type: EXPERIMENTAL
Intervention: Granulocyte‐macrophage‐colony stimulating factor (GM‐CSF) at a dose of 10 microg/kg per day, administered subcutaneously, on a 14‐days‐on/14‐days‐off schedule
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at a dose of 400 mg administered orally 4 times per day
Number of subjects: 24
Study: 7977546

Group type: EXPERIMENTAL
Intervention: Intramyometrial 15‐methyl prostaglandin F2 alpha, 125 micrograms
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous oxytocin, 20 U
Number of subjects: 60
Study: 2690762

Group type: EXPERIMENTAL
Intervention: 5,6 benzo-[alpha]-pyrone (coumarin, '56 BaP')
Number of subjects: 169

Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 169
Study: 30145307

Group type: EXPERIMENTAL
Intervention: MDD-SAD group
Number of subjects: 162

Group type: COMPARATOR
Intervention: MDD group
Number of subjects: 162

Group type: COMPARATOR
Intervention: HC group
Number of subjects: 162
Study: 27174580

Group type: EXPERIMENTAL
Intervention: Premeal insulin
Number of subjects: 40

Group type: COMPARATOR
Intervention: No insulin (control)
Number of subjects: 40
Study: 26577187

Group type: EXPERIMENTAL
Intervention: Urine collection with preservatives (thymol, toluene, and boric acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urine collection without preservatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine collection protocol in NEPTUNE
Number of subjects: 0
Study: 24278119

Group type: EXPERIMENTAL
Intervention: In-group partner during the Joint Simon Task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Out-group partner during the Joint Simon Task
Number of subjects: 0
Study: 21144709

Group type: EXPERIMENTAL
Intervention: Oral piroxicam 20mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sublingual piroxicam 20mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 53
Study: 18499605

Group type: EXPERIMENTAL
Intervention: Low-dose sevoflurane inhalation (0.5-1 vol % end-tidal concentration in oxygen 50 vol %)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhaling oxygen (50 vol %) alone
Number of subjects: 10
Study: 16864104

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Tube drainage (TD)
Number of subjects: 53
Study: 12752022

Group type: EXPERIMENTAL
Intervention: Short cognitive-behavioral group treatment
Number of subjects: 32
Study: 9807980

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg) + Dextroamphetamine (10 mg)
Number of subjects: 24
Study: 7701460

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion for 60 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP) infusion for 60 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion for 60 minutes
Number of subjects: 8
Study: 2715552

Group type: EXPERIMENTAL
Intervention: LY171883 (400 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 324270

Group type: EXPERIMENTAL
Intervention: Methylcellulose (Celevac) - two tablets daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo - two tablets daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylcellulose (Celevac) - two tablets daily (crossover group)
Number of subjects: 30
Study: 31294134

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 132
Study: 28651526

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study: 24435717

Group type: EXPERIMENTAL
Intervention: Guideline-based asthma actions delivered at the index visit
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Preventive medication action at the time of an office visit
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Asthma morbidity assessment at 2 month follow-up
Number of subjects: 177
Study: 22470548

Group type: EXPERIMENTAL
Intervention: Motor learning with visual feedback
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Motor learning without visual feedback
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Simple hand movements
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control condition (untrained hand)
Number of subjects: 15
Study: 19437082

Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 19
Study: 17518554

Group type: EXPERIMENTAL
Intervention: Cautionary instructions regarding believability of participants' simulation
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Different financial incentive levels
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Comorbid psychiatric diagnostic training (PTSD + MDD vs. PTSD only)
Number of subjects: 510
Study: 15226632

Group type: EXPERIMENTAL
Intervention: Carvedilol (10 mg twice a day)
Number of subjects: 160
Study: 11268711

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg for 24 weeks
Number of subjects: 90
Study: 9822940

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg three times daily)
Number of subjects: 43
Study: 8130042

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 20 ml
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 20 ml
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.9% NaCl 20 ml (Control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (including controls)
Number of subjects: 45
Study: 2808260

Group type: EXPERIMENTAL
Intervention: Methylphenidate (dosages: 0.3 mg/kg, 0.6 mg/kg, 1.0 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 320829

Group type: EXPERIMENTAL
Intervention: Gangliosides
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31822294

Group type: EXPERIMENTAL
Intervention: Training + Feedback + Consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training Only
Number of subjects: 0
Study: 27666392

Group type: EXPERIMENTAL
Intervention: Deep breathing before a timed math test
Number of subjects: 122
Study: 26359327

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 day patch (12.5-50.0 µg/h)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476
Study: 23370149

Group type: EXPERIMENTAL
Intervention: Group A (n=39) received 0.1 ml of purified Vero cell rabies vaccine (PVRV) intradermally on days 0 and 21.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Group B (n=16) received 0.5 ml of PVRV intramuscularly on days 0, 7, and 21.
Number of subjects: 55
Study: 21078710

Group type: EXPERIMENTAL
Intervention: Sonographic image-guided injection
Number of subjects: 244

Group type: COMPARATOR
Intervention: Conventional palpation-guided injection
Number of subjects: 244
Study: 19268499

Group type: EXPERIMENTAL
Intervention: Allopregnanolone (intravenous administration)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (intravenous administration)
Number of subjects: 28
Study: 16903602

Group type: EXPERIMENTAL
Intervention: Centro-square needling and triple needling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine acupuncture therapy with motor therapy
Number of subjects: 60
Study: 16516010

Group type: EXPERIMENTAL
Intervention: Bladder retraining
Number of subjects: 708

Group type: COMPARATOR
Intervention: Antimuscarinic therapy
Number of subjects: 708
Study: 14748458

Group type: EXPERIMENTAL
Intervention: Using both hands
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Under the left arm
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Under the right arm
Number of subjects: 48

Group type: COMPARATOR
Intervention: Running without the ball
Number of subjects: 48
Study: 10501823

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation of 200 mg p.o. per day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dialysis treatment
Number of subjects: 19
Study: 8568117

Group type: EXPERIMENTAL
Intervention: Vitamin C (0.5 g twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2041034

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 38

Group type: COMPARATOR
Intervention: prazosin
Number of subjects: 38
Study: 7192117

Group type: EXPERIMENTAL
Intervention: Sulfamethoxydiazine administered with a test meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfamethoxydiazine administered with a high-lipid meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfamethoxydiazine administered with high-protein or high-carbohydrate meals
Number of subjects: 0
Study: 31995215

Group type: EXPERIMENTAL
Intervention: Simulated black callers
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Simulated Hispanic callers
Number of subjects: 804
Study: 31567447

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pharmacological treatments
Number of subjects: 0
Study: 28887058

Group type: EXPERIMENTAL
Intervention: Resistance exercise program performed 3 times a week during HD sessions
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 44
Study: 25869993

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 1601
Study: 24257657

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Group 1)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Tissucol (fibrinogen and thrombin) (Group 2)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (Group 3)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Routine hemostasis (Control Group 4)
Number of subjects: 172
Study: 20931346

Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (CT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 19167797

Group type: COMPARATOR
Intervention: Control diet (15% energy from protein)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable (FV) diet (15% energy from protein)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: DASH diet (18% energy from protein)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable (FV) diet
Number of subjects: 378
Study: 17896083

Group type: EXPERIMENTAL
Intervention: Ramsay scale
Number of subjects: 237